Latest Breaking News On - Thomas pozefsky - Page 1 : comparemela.com

A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication. The clinical trial will enroll people for whom two to four doses of a COVID-19 mRNA vaccine did not elicit a detectable antibody response. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring and funding the Phase 2 trial, called COVID Protection After Transplant–Immunosuppression Reduction, or CPAT-ISR. “Eliciting a protective immune response to COVID-19 vaccines in someA study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication. The clinical trial will enroll people for whom two to four doses of a COVID-19 mRNA vaccine did not elicit a ►

United statesUnited kingdomThomas pozefskyAnthonys fauciJohns hopkins university in baltimoreNational institute of allergyNational institutes of healthNational instituteInfectious diseasesNational institutesAfter transplantImmunosuppression reductionJohns hopkins universityHealth amp beauty